Literature DB >> 24925503

Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype.

Cheng-Chia Lee1, Mary Lee Vance, M Beatriz Lopes, Zhiyuan Xu, Ching-Jen Chen, Jason Sheehan.   

Abstract

PURPOSE: The subtypes of somatotroph-cell pituitary adenomas have been correlated with clinical and histopathological variables. Densely granulated somatotroph-cell (DG) adenomas are typically highly responsive to somatostatin analog drugs, whereas sparsely granulated somatotroph-cell (SG) are less responsive. The aim of the study is to determine the effect of stereotactic radiosurgery (SRS) on remission and development of new pituitary deficiency according to the different subtypes of growth hormone (GH) secreting adenomas.
METHODS: A total of 176 patients underwent SRS for acromegaly at the University of Virginia. Diagnosis of acromegaly was based on the combination of clinical features and biochemical assessment including the serum GH level, and age- and gender-matched serum insulin-like growth factor-1 level. All patients underwent endocrine and neuro-imaging evaluations before and after SRS. Histological specimens were available in 73 patients.
RESULTS: The histopathological examination showed 34 patients had a DG adenoma, 19 had a SG adenoma, eight had a mixed DG/SG pattern, while other rare mixed subtypes were present in 12 patients. Patients who had a SG adenoma were more likely to be younger and female, and the SG adenomas appeared to be more invasive into the cavernous sinus. With a median follow-up of 67 months (range 6-188 months), 55/73 patients (75.3%) achieved remission. The median time to remission was 26 months (range 6-102 months). The actuarial remission rates in the DG adenoma group at 2, 4, and 6 years post-radiosurgery were 35.1, 71.4, and 79.3%, respectively, while those in SG adenoma group were 35.4, 73.1, and 82.1%, respectively.
CONCLUSION: While patients who had a SG adenoma may be less responsive to medical therapy, they exhibited similar responses to SRS as patients with a DG adenoma. For SG adenomas, which respond less well to medical therapy, earlier SRS may be reasonable for consideration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24925503     DOI: 10.1007/s11102-014-0578-5

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  25 in total

1.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

Review 2.  Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization.

Authors:  Joel S Greenberger; Michael W Epperly
Journal:  In Vivo       Date:  2007 Mar-Apr       Impact factor: 2.155

3.  Downregulation of E-cadherin and its undercoat proteins in pituitary growth hormone cell adenomas with prominent fibrous bodies.

Authors:  Bing Xu; Toshiaki Sano; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

4.  Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.

Authors:  Roberto Attanasio; Paolo Epaminonda; Enrico Motti; Enrico Giugni; Laura Ventrella; Renato Cozzi; Mario Farabola; Paola Loli; Paolo Beck-Peccoz; Maura Arosio
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

Review 5.  Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife.

Authors:  Jay Jagannathan; Chun-Po Yen; Nader Pouratian; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

6.  Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.

Authors:  Abdulkader Obari; Toshiaki Sano; Kenichi Ohyama; Eiji Kudo; Zhi Rong Qian; Akiko Yoneda; Nasim Rayhan; Muhammad Mustafizur Rahman; Shozo Yamada
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

7.  HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response.

Authors:  Nabieh Ayoub; Anand D Jeyasekharan; Juan A Bernal; Ashok R Venkitaraman
Journal:  Nature       Date:  2008-04-27       Impact factor: 49.962

8.  The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.

Authors:  Stine L Fougner; Olivera Casar Borota; Jens Petter Berg; John K Hald; Jon Ramm-Pettersen; Jens Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  2007-10-17       Impact factor: 3.478

9.  Long-term results of stereotactic radiosurgery in secretory pituitary adenomas.

Authors:  Frederic Castinetti; Mariko Nagai; Isabelle Morange; Henry Dufour; Philippe Caron; Philippe Chanson; Christine Cortet-Rudelli; Jean-Marc Kuhn; Bernard Conte-Devolx; Jean Regis; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2009-06-09       Impact factor: 5.958

10.  Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register.

Authors:  Christof Schöfl; Holger Franz; Martin Grussendorf; Jürgen Honegger; Cornelia Jaursch-Hancke; Bernhard Mayr; Jochen Schopohl
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

View more
  14 in total

1.  Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.

Authors:  Liang Lv; Yong Jiang; Senlin Yin; Yu Hu; Cheng Chen; Weichao Ma; Shu Jiang; Peizhi Zhou
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

Review 2.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Growth hormone-producing pituitary adenomas in childhood and young adulthood: clinical features and outcomes.

Authors:  Yuichi Nagata; Naoko Inoshita; Noriaki Fukuhara; Mitsuo Yamaguchi-Okada; Hiroshi Nishioka; Takeo Iwata; Katsuhiko Yoshimoto; Shozo Yamada
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 4.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.

Authors:  Amy A Swanson; Dana Erickson; Diane Mary Donegan; Sarah M Jenkins; Jamie J Van Gompel; John L D Atkinson; Bradley J Erickson; Caterina Giannini
Journal:  Pituitary       Date:  2020-10-19       Impact factor: 4.107

6.  Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery.

Authors:  Mohana Rao Patibandla; Zhiyuan Xu; Jason P Sheehan
Journal:  J Neurooncol       Date:  2018-02-07       Impact factor: 4.130

7.  Long-term results of hypofractionated stereotactic radiotherapy with CyberKnife for growth hormone-secreting pituitary adenoma: evaluation by the Cortina consensus.

Authors:  Hiromitsu Iwata; Kengo Sato; Ryutaro Nomura; Yusuke Tabei; Ichiro Suzuki; Naoki Yokota; Mitsuhiro Inoue; Seiji Ohta; Shozo Yamada; Yuta Shibamoto
Journal:  J Neurooncol       Date:  2016-03-09       Impact factor: 4.130

8.  Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.

Authors:  Julieann C Lee; Melike Pekmezci; Jonathan L Lavezo; Hannes Vogel; Laurence Katznelson; Merav Fraenkel; Griffith Harsh; Mohanpal Dulai; Arie Perry; Tarik Tihan
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

Review 9.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 10.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.